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Background: In Europe, dietary management of isovaleric acidemia (IVA) may vary widely. There is limited col-
lective information about dietetic management.
Aim: To describe European practice regarding the dietary management of IVA, prior to the availability of the E-
IMD IVA guidelines (E-IMD 2014).
Methods:A cross-sectional questionnairewas sent to all European dietitianswhowere eithermembers of the So-
ciety for the Study of Inborn Errors of Metabolism Dietitians Group (SSIEM-DG) or whom had responded to pre-
vious questionnaires on dietetic practice (n = 53). The questionnaire comprised 27 questions about the dietary
management of IVA.
Results: Information on 140 patientswith IVA from39 centreswas reported. 133 patients (38 centres)were given
a protein restricted diet. Leucine-free amino acid supplements (LFAA)were routinely used to supplement protein
intake in 58% of centres. The median total protein intake prescribed achieved the WHO/FAO/UNU [2007] safe
levels of protein intake in all age groups. Centres that prescribed LFAA had lower natural protein intakes in
most age groups except 1 to 10 y. In contrast, when centres were not using LFAA, themedian natural protein in-
take met WHO/FAO/UNU [2007] safe levels of protein intake in all age groups. Enteral tube feeding was rarely
prescribed.
Conclusions: This survey demonstrates wide differences in dietary practice in the management of IVA across Eu-
ropean centres. It provides unique dietary data collectively representing European practices in IVAwhich can be
used as a foundation to compare dietarymanagement changes as a consequence of theﬁrst E-IMD IVA guidelines
availability.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Isovaleric acidemia (IVA) (McKusick 243500) is a rare inherited
condition, caused by a deﬁciency of the mitochondrial enzyme
isovaleryl-CoA dehydrogenase (EC 1.3.99.10), leading to accumulation
of isovaleryl-CoA and its metabolites including free isovaleric acid, 3-
hydroxyisovalerate and N-isovalerylglycine [1]. The major goal of IVA
management is to reduce the production and increase excretion of
isovaleryl-CoA. This is achieved by: 1) limiting leucine intake via protein
restriction [2–4]; 2) enhancement of alternative metabolic pathways
using carnitine [5,6] and glycine [7,8] which conjugate with isovaleryl-
CoA to produce the non-toxic compounds isovalerylglycine and
isovalerylcarnitine; and 3) application of an emergency management
protocol at times of metabolic stress (e.g. illness and fasting). However,
partly due to IVA's heterogeneity, its rarity, shortage of large,multi-cen-
tre longitudinal studies and long-term outcome data, there is disagree-
ment regarding optimal dietary management. Almost all reports are
from case studies or small case series only.
The ﬁrst case studies of IVA reported signs of dietary protein intoler-
ance typically with episodes of vomiting, lethargy and acidosis with
ketonuria after increased intake of protein-rich foods [9,10]. Many pa-
tients maintain long term metabolic stability on dietary protein restric-
tion only [1,11–18]. In fact, themajority of IVA case studies advise some
protein restriction [1–7,9,11,14–16,19–30] but with wide differences in
the amount of natural protein given. Some centres prescribe less than
theWHO/FAO/UNU2007 safe levels of protein intake [31] andmay spe-
ciﬁcally calculate and control leucine intake supplemented with leu-
cine-free L-amino acid supplements (LFAA) [3,5,22,23,26–29,32–35].
In September 2014, the web based E-IMD IVA guidelines [36] advo-
cated that natural protein intake be restricted to reduce the isovaleric
acid burden but should supply at least the WHO/FAO/UNU 2007 safe
levels of protein intake [31]. The use of LFAA was not discussed [36]
and some considered they may provide little clinical beneﬁt and thus
provide extra burden to patients and families and unnecessary expense
to health services.
This paper aims to describe European practice regarding the dietary
management of IVA prior to the introduction of the E-IMD IVA guide-
lines in 2014.
2. Material and methods
A cross-sectional questionnaire was sent to all European dietitians
who were either members of the Society for the Study of Inborn Errors
ofMetabolismDietitians Group (SSIEM-DG) orwhomhad responded to
previous questionnaires on dietetic practice (n= 53) [37]. We request-
ed dietitians cascade the questionnaire to other dietitians and/or physi-
cians within their own country between July and August 2014. The
questionnaire consisted of 27 multiple choice and short answer ques-
tions. The questions were aimed at patients on dietary treatment. The
following data were collected by age group: total protein intake pre-
scribed, amount of natural protein and use of LFAA. Speciﬁc questions
were asked about: special low protein foods, energy, vitamin and min-
eral supplements, use of enteral feeding, monitoring, treatment criteria
and treatment drugs. The resultswere divided into geographical regions
to examine trends in protein prescription. The groupingswere:Western
Europe Group A (Netherlands, Belgium, France),Western EuropeGroup
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B (Germany, Switzerland, Austria), Eastern Europe (Poland), Southern
Europe (Italy, Spain and Portugal), and Northern Europe (Denmark,
Norway, Sweden and UK).
Clinical outcome data or patient speciﬁc data were not included in
this questionnaire. Therefore, ethical approval was not required.
2.1. Statistical analysis
Data were analysed using descriptive statistics (percentage of total
responses, means or medians). Prior to analysis, responses to some
open answer questions were grouped or categorised according to an-
swers received.
3. Results
Dietitians from 53 centres, representing 14 countries returned ques-
tionnaires. Fourteen of 53 centres reported they had no patients with
IVA. For each country a median of 3 centres responded (range 1–14).
3.1. Patient description
In total, 140 patients with IVA were reported. Seven of 140 patients
were excluded from analysis as they were not prescribed a protein re-
striction. Therefore 133 patients from 38 centres were on protein re-
striction with a median of 2 patients (range 1–17) per centre.
The numbers of centres and patients in each geographical grouping
were: Western Europe Group A, n = 14 centres, 44 patients; Western
Europe Group B, n = 6 centres, 24 patients; Eastern Europe, n = 1 cen-
tre, 8 patients; Southern Europe, n=4 centres, 9 patients; andNorthern
Europe, n=13 centres, 48patients. In the 133 IVApatients presentation
agewas: neonatal, n= 81 (61%); late, n=48 (36%), and unknown, n=
4 (3%). Patients were distributed in the following age ranges at the time
of questionnaire completion: b1 y (n = 7), 1–10 y (n = 71), 11–16 y
(n = 31) and N16 y (n = 24).
3.2. Total protein prescription
All centres distributed by region and age range are presented in
Fig. 1. Total protein intake (g/kg/day) in almost all centres (32 of 38,
84%) met WHO/FAO/UNU safe levels of protein intake [31].
Twenty centres (53%) prescribed total protein prescription accord-
ing to theWHO/FAO/UNU safe levels of protein intake [31], and 15 cen-
tres (39%) used the countries national reference protein intake as a
guide for protein prescription. The median total protein prescription
(g/kg/day) with and without LFAA is given in Table 1.
The following criteria were used by all centres for adjusting protein
prescription: quantitative plasma amino acid proﬁles, growth and
severity of IVA. Protein prescription was a combined decision between
medical doctors and dietitians in 24 centres (63%), medical doctors
only in 11 centres (29%) and a dietitian's decision only in 2 centres
(5%). One centre did not answer this question.
3.3. Natural protein prescription
The median natural protein prescription (g/kg/day) compared with
WHO/FAO/UNU safe levels of protein, with and without LFAA is given
in Table 2. In Fig. 2, natural protein prescription is presented by region
and age. Almost half of the centres (n = 18; 47%) prescribed natural
protein intakes belowWHO/FAO/UNU 2007 safe levels of protein intake
[27] in at least one age range. However, the use of LFAA in 12 (66%) cen-
tres improved protein intake allowing safe levels to be achieved. Five of
38 centres (13%) prescribed a low protein diet (without LFAA) that did
not provide safe levels of protein intake [27] in patients above 11 y (cen-
tres from France n = 2; UK, n = 2; and Italy, n = 1).
Ten centres (26%) reported avoiding animal protein as part of the
natural protein allowance. Seven of these centres used LFAA to supple-
ment natural protein intake.
3.4. Prescription of LFAA
LFAA were used routinely to supplement protein intake by 23 of 38
(61%) centres (Fig. 3). The amount of LFAA prescribed per kg is given in
Table 1. The median percentage of total protein provided by LFAA was
over 40% (range17–82%) in all age groups. The numbers of centres pre-
scribing LFAA declined from 10 years of age [aged 0 to 12 months, 67%
(n = 4 centres); 1 to 10 y, 67% (n = 18 centres), 11 to 16 y, 50%
(n = 9 centres) and N16 y of age, 43% of centres (n = 6 centres)].
None of the UK centres prescribed LFAA for IVA. Centres within coun-
tries that varied in their approach to using LFAA were Austria, Belgium,
France, Germany, Italy and Netherlands.
LFAA were given in divided doses throughout the day mixed with
water/fruit juice or as a puree. The preferred LFAA were for: infants, a
leucine-free infant formula supplemented with carbohydrate, fats, vita-
mins and minerals, and patients over 1 y, a leucine-free L-amino acid
supplement (powder/liquid) containing carbohydrate, vitamins and
minerals. LFAA without added vitamins and minerals were rarely used.
3.5. Nutritional support
Only 8 of 133 patients (6%) were given tube feeds (for neurological
dysfunction and feeding difﬁculties). Of this group all had gastrostomy
tubes and 3 of 8 were on nocturnal enteral feeds only.
The majority of centres (34 of 38; 89%) used special low protein
foods such as low protein pasta but the amount varied according to in-
dividual patient needs and the dietary practices of local centres. Seven-
ty-four percent (28 of 38 centres) prescribed a low protein milk
replacement instead of cow's milk. Only 11% (15 of 133) of patients
were given additional energy supplements.
3.6. Monitoring
All centres monitored weight, height, quantitative plasma amino
acids and nutritional blood markers. The frequency was age dependent
(3–12 monthly) with infants and young children (pre-school age)
assessed more frequently. Nutritional markers included: quantitative
amino acids, zinc, selenium, haemoglobin, ferritin and vitamins B12
(and plasma MMA), D, A and E. Some centres reported monitoring es-
sential fatty acids (23 centres; 60%), but at infrequent intervals.
3.7. Drugs treatment
Most centres reported using carnitine (37 centres, 97%) and glycine
(29 centres, 76%) as a standard treatment approach. Nitrogen scavenger
Fig. 1.Mean total protein prescription to IVA patients by centre in each age range (n= 38
centres).
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drugs where used by 2 centres (5%) but only to treat hyperammonemia
at initial presentation. Laxatives for constipation were used by 7 centres
(18%).
4. Discussion
This multicentre pan European survey describes the dietary man-
agement of 133 patients with IVA on protein restriction prior to the in-
troduction of the E-IMD IVA guidelines. This provides a foundation to
compare any changes in dietary approach as a consequence of the avail-
ability of the ﬁrst European guidelines. Most centres managed only
small numbers of IVA patients, constraining the development of dietetic
expertise with this condition. There was little consensus in dietary ap-
proach. Centres that prescribed a natural protein restriction only, gener-
ally achieved the WHO/FAO/UNU [2007] safe levels of protein intake
[31] but in 5 of these centres, particularly in patients ≥11 years of age,
natural protein intakes were well below safe levels.
LFAAwere used by almost two thirds of Europeanmetabolic centres
to compensate for the low natural protein prescription in order to meet
safe levels of protein intake. The need for LFAA has been challenged
[1,11–18] and the use of LFAA is not advocated by the IVA-EIMD guide-
lines [36]. There is some suggestion that LFAA may correct amino acid
imbalance or deﬁciency [27,30,38,39] but the effectiveness of this is
unknown and remains unstudiedwith severe natural protein restriction
appearing unnecessary. There is limited published IVA patient outcome
data that describes dietary management in depth. In a recent study,
data from a patient registry outlined 45 patients with IVA who had
baseline height and weight z scores that were close to zero but dietary
intake was unreported [40]. In 4 adults with IVA, managed with low
protein diets only, had normal growth and no progressive disease
[17]. In a group of 21 IVA patients, catabolic episodes mainly occurred
in early childhood and protein intake did not appear to be a major
precipitating factor [41]. Generally, long term treatment with carnitine,
glycine and a low protein diet (with or without LFAA) appears to lead
to relative metabolic stability, particularly after the early childhood
years.
Geographical location appeared to have a large inﬂuence on the pre-
scription of LFAA with more centres prescribing in Western Europe A
(79% of centres), Southern Europe (75% of centres), Western Europe B
(67% of centres), and Eastern Europe (the only centre participating
used LFAA). Less LFAA was prescribed in Northern Europe (only 31%
of centres), and no centres in the UK used LFAA (Fig. 3). In addition,
companies that produce LFAA for IVA only supply a limited range.
These aremainly unﬂavoured with narrow presentation choice (mainly
powders). It is possible adherencemay be sub-optimal but this question
was not asked and remains unreported in IVA.
Table 1
Descriptive statistics comparing centres (using/not using LFAA) for dietary prescription of: total protein (g/kg), natural protein (g/kg), LFAA (g/kg) and % of protein provided by LFAA com-
pared with total protein prescription.
Centres using LFAA Centres not using LFAA
Age
0–6 m
(n = 2)
Age
7–12 m
(n = 2)
Age
1–10 y
(n = 40)
Age
11–16 y
(n = 16)
Age
N16 y
(n = 5)
Age
0–6 m
(n = 3)
Age
7–12 m
(n = 0)
Age
1–10 y
(n = 31)
Age
11–16 y
(n = 15)
Age
N16 y
(n = 19)
Total protein (g/kg)
Median 2.2 1.9 1.7 1.1 1.1 1.6 None reported 1.3 1.0 0.9
Min 1.7 1.8 0.9 1.0 1.0 1.4 1.0 0.2 0.5
Max 2.6 2.0 2.3 1.5 1.5 1.8 2.0 1.8 1.1
Natural protein (g/kg)
Median 1.1 0.4 1.0 0.7 0.7 1.6 None reported 1.3 1.0 0.9
Min 1.0 0.4 0.4 0.4 0.4 1.4 1.0 0.2 0.5
Max 1.1 0.5 1.9 1.0 0.8 1.8 2.0 1.8 1.1
LFAA (g/kg)
Median 1.1 1.5 0.7 0.5 0.6 0 None reported 0 0 0
Min 0.7 1.3 0.2 0.4 0.3 0 0 0 0
Max 1.5 1.7 1.2 0.6 0.8 0 0 0 0
% amount of total protein from LFAA
Median 50 77 44 42 48 0 None reported 0 0 0
Min 41 72 17 29 27 0 0 0 0
Max 58 82 75 60 64 0 0 0 0
LFAA: leucine free L-amino acids.
n: number of patients.
Table 2
Comparison of natural protein and total protein with WHO/FAO/UNU [2007] safe levels of protein intake for all centres.
Centres using LFAA Centres not using LFAA
Age 0–6 m
(n = 2)
7–12 m
(n = 2)
1–10 y
(n = 40)
11–16 y
(n = 16)
N16 y
(n = 5)
0–6 m
(n = 3)
7–12 m
(n = 0)
1–10 y
(n = 31)
11–16 y
(n = 15)
N16 y
(n = 19)
Natural protein (g/kg)
Median 1.1 0.4 1.0 0.7 0.7 1.6 None reported 1.3 1.0 0.9
WHO/FAO/UNU 2007 1.31 1.14 0.94a 0.89a 0.84 1.31 1.14 0.94a 0.89a 0.84
% intake compared to WHO reference value 2007 84 35 106 79 83 122 – 138 112 107
Total protein (g/kg)
Median 2.2 1.9 1.7 1.1 1.1 1.6 None reported 1.3 1.0 0.9
WHO/FAO/UNU 2007 1.31 1.14 0.94a 0.89a 0.84 1.31 1.14 0.94a 0.89a 0.84
% intake compared to WHO reference value 2007 168 167 181 124 131 122 – 138 112 107
LFAA: leucine free L-amino acids.
n: number of patients.
a Mean protein values for ages 1–10 y, 11–16 y taken for WHO/FAO/UNU [2007] recommendations.
19A. Pinto et al. / Molecular Genetics and Metabolism Reports 12 (2017) 16–22
The IVA E-IMD guidelines [36] recommend that natural protein in-
take should be restricted to reduce the isovaleric acid burden but
ought to supply at least the safe levels of protein intake advocated by
WHO/FAO/UNU 2007 [31]. They emphasise that over-restriction of nat-
ural protein could lead to catabolism and metabolic instability [42].
From case reports, patients are able to maintain metabolic stability
when consuming at least theWHO/FAO/UNU safe levels of protein/leu-
cine intake although some younger patients have tolerated double this
amount [1,14,15,24]. In IVA, there are no reported differences in leu-
cine/protein prescription for age, growth rate and severity of disorder.
There are also no case reports describing protein intake in adolescents
and adults or for patients with the milder 932C-T mutations. Although
in our cohort some of the older patients, in particular, were prescribed
less than safe levels of protein intake, it is possible that their actual nat-
ural protein intake was higher but we did not collect this data.
Leucine is an essential amino acid; it plays an important role in the
regulation of metabolism, promotes global protein synthesis by signal-
ling an increase in translation [43,44], promotes insulin release [45]
and inhibits autophagic protein degradation [46]. Over restriction will
lead to anorexia, triglyceride lipolysis [47], weight loss [48], and
amino acid imbalance. Leucine provides 10% of the amino acid content
of animal protein but only 6% of vegetable protein [49]. In this study, al-
most one third of centres used only low biological food sources to pro-
vide natural protein intake. This may potentially lead to leucine
deﬁciency, which has been reported in IVA children [50].
Generally, in IVA, emphasis has been placed on protein intake but
maintenance of energy intake may be as important as protein restric-
tion. In an early study, Millington et al. [51] demonstrated that the turn-
over of endogenous protein, rather than dietary protein intake, is the
main cause for the production of toxic metabolites in IVA. He suggested
that suppression of endogenous catabolism ismore effective than exog-
enous dietary protein restriction. Therefore, although therewas low use
of tube feeding (8 of 133patients) in this survey, overall evidencewould
suggest that attention should be paid to adequate energy intake when
patients are both stable and during metabolic stress.
There are some limitations in this survey. Initially participant inter-
pretation of some questions was inconsistent, but all answers were
quality checked with individual participants until we were certain
datawas interpreted correctly. No datawas collected about patient clin-
ical outcome, disease severity or detailed information about drug treat-
ments which may have impacted on centres practices with protein
prescription. Also data was collected about dietary prescriptions rather
than actual dietary intake.
There remainsmuch to be done to deﬁne the optimumdietaryman-
agement of IVA considering all age groups and disorder severity. The
prescription of median natural protein intake was below safe levels of
protein intake when centres were giving LFAA. Overall, there may be
‘over restriction’ of natural protein and unnecessary use of LFAA creat-
ing a diet that is burdensome and expensive [51,52], particularly in
older patients who have fewer episodes of metabolic instability. It is
also important that further guidelines should differentiate dietary man-
agement for the “classic” IVA and the “mild” phenotype [52]. This study
provides baseline data from a large cohort of IVA patients and will help
enable the development of controlled trials to further investigate die-
tary management and help standardise treatment.
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